Health Innovations invests in Aidence together with Northzone, HenQ and MSB Haaglanden. Aidence improves healthcare using computer-aided diagnostics, with an initial application for lung cancer detection. Aidence’s software provides faster, cheaper and more accurate diagnoses of X-ray, MRI and CT images. The core technology is deep learning, a revolutionary type of artificial intelligence that allows image recognition at a human level. The artificial intelligence software platform will be CE certified for the first medical application within 6 months. This initial application will also be placed on the market with the available resources.
Together with Holland Ventures, Health Innovations invests in Prolira in order to make delirium detection better and faster. Prolira develops a medical device to detect delirium with a three-point EEG measurement. The company is a spin-off of the University Medical Centre Utrecht. Delirium is common in hospital patients, with often severe consequences. With the investment, Prolira has the means to work on the first steps to introduce the delirium detector on the market.
Health Innovations invests in swyMed to accelerate the growth of the E-health company. Operating under the name swyMed, remote working in healthcare is facilitated using video links coupled to diagnostic equipment, hospital information systems and media storage, such as x-rays. This allows a remote diagnosis to be made in real time in a video connection between two care professionals. This also works when mobile and under all circumstances, e.g. for sharing video and measurement data from an ambulance with a specialist in a hospital. The swyMed platform supports telephones, computers and tablets. The investment is used for the further development of the platform and for strengthening the sales team.
INKEF Capital and Gilde Healthcare Partners joined in a new investment round and existing investors also participated, including Health Innovations. The investment allows NightBalance to intensify and expand the sales and marketing of the Sleep Position Trainer (SPT) in Europe and to prepare access to the US market. NightBalance’s SPT trains patients not to sleep on their back so that position-dependent sleep apnoea no longer occurs.
De Friesland Participatiefonds and Participatiemaatschappij Oost Nederland BV invested in Stroke2prevent in a new investment round. Stroke2prevent’s A-View enables physicians to better monitor the aorta for arteriosclerosis through means of an echocardiogram. The parts of the arteries with arteriosclerosis can be avoided during surgery. This reduces the risk of calcification coming loose and the resulting risk of a stroke. Health Innovations, amongst others, invested in the first round, and the resulting resources allowed A-view to be introduced in several hospitals. With the money from the new round, the A-view will now also be available in several European countries and preparations are underway for US market introduction.
In a new investment round, INKEF and LSP together invested €10 million in ViCentra, the manufacturer of the Kaleido insulin pump for diabetes patients. ViCentra started in 2013 with investments from Health Innovations and INKEF. The new resources were used to introduce the Kaleido on the European market and preparations are underway for the US market.
Health Innovations invested in Cloud9 Software to accelerate the company’s growth and to further the development of the software. Cloud9 Software delivers software (research manager) to healthcare organisations and commercial research institutions that support clinical research. Cloud9 Software also has a solution for registering, collecting, validating and reporting data on the quality of care within hospitals. A good market position has since been acquired, which will be expanded further in the coming years with the investment and support from Health Innovations.
Health Innovation Fund invests in Livassured to enable the final stage of NightWatch’s product development and market introduction. The NightWatch is a monitoring device for epilepsy patients to indicate nightly attacks with more certainty. Livassured products are expected to have a positive impact on overall healthcare and on the patient and his/her care.
Health Innovations sold its interest in Novicare to Gilde Healthcare Services. Novicare provides treatment services for nursing homes. Together with Gilde, Novicare can become active throughout the Netherlands in the coming years and further expand its service.
Health Innovations sold its interest in Zibber to Ooperon. Zibber provides image telephony and monitoring solutions for the elderly, caregivers and healthcare providers. Through this acquisition, Ooperon improves its position as provider of personal security and communication in nursing home care.
Health Innovations invested in Gannet for further market introduction and the first steps in an international rollout. Gannet makes an innovative surgical implant designed for setting femoral neck fractures (medial column fractures). What makes this implant unique is the rotational stability combined with a low implant volume. The implant allows the patient to walk again quite quickly. Using the Gannet helps to reduce the number of complications and reoperations, which is good for the patient and reduces healthcare costs.
Health Innovations, together with Thuja Capital and Van Herk Ventures, invested in the second financing round of NightBalance for the international rollout of the Sleep Position Trainer (SPT). The Sleep Position Trainer is a device that intelligently teaches people with positional sleep apnoea to no longer sleep on their backs. The SPT is now sold in seven countries. Health Innovations and Thuja Capital invested in the first round and Van Herk Ventures enters this new round as an investor.
Health Innovations invests in ANW Nederland. ANW Nederland organises medical accessibility services for long-term care. ANW Nederland provides an affordable and reliable service to healthcare institutions using triage, scheduling and good ICT support. As a result, the expertise of the specialised physicians is available where it is most useful, namely during the day with clients in the healthcare institution.
Health Innovations, together with Inkef, invests in the development of a new generation of insulin pumps for diabetes patients. ViCentra developed a small insulin pump that offers the diabetic patient as much freedom of movement as possible and that can accurately manage his/her glucose level. By cleverly developing the pump with new technologies, ViCentra can keep costs low and thus make the pump available to a large group.
Health Innovations sold its interest in Netmedical to MediZorg. Netmedical offers solutions for patients who need medical care at home, especially in the area of diabetes care and light therapy, using patientdossier.nl and telemonitoring. MediZorg wants to use its acquisition of Netmedical to strengthen its position in eHealth.
Health Innovations invests in NovioSense. The company develops a sensor for measuring glucose in the eye. The sensor measures glucose concentrations in the eye fluid and sends a message to a device or mobile phone. Type 1 diabetes patients can use this system for continuous glucose measurement as an alternative to the current method of taking a blood sample. In addition to Health Innovation Fund I, PPM Oost, Fraunhofer Gesellschaft and Interreg also invest in a joint financing of €1.6 million.
Health Innovations starts Health Innovation Fund II. Following the success of the Health Innovation Fund I, the second venture capital fund is now starting. With Coöperatie VGZ, ABN AMRO and Mediq as investors, the fund will invest €8 million in 10 to 12 start-up companies in the coming years. Health Innovation Fund II will invest in new medical technologies and treatment methods focused on prevention, care and well-being. Ten investments in promising companies have already been made with the first fund. Almost all the investments are performing as expected. According to the parties involved, innovation is not just a prerequisite for keeping healthcare affordable, it’s also important for the further improvement of healthcare quality.
The Health Innovation Fund invests in Stroke2prevent. The company markets the A-view, a medical device developed to treat strokes due to cardiac surgery and cardiological aortic valve replacement. The A-view can reveal arteriosclerosis in the aorta so that the medical team can use this information to determine the correct operating strategy. The A-view is scientifically validated, and the method is used daily for cardiac surgery and cardiological catheter interventions. The investment enables Stroke2prevent to better rollout the product in the Dutch and international markets.
Together with Thuja Capital, the Health Innovation Fund invests in NightBalance. The start-up from Delft develops and markets innovations for patients with sleep apnoea. This condition causes regular stops in breathing which lead to all kinds of health risks due to oxygen deficiency. There are an estimated 300,000 people with sleep apnoea in the Netherlands. NightBalance’s non-invasive method adds a patient friendly solution to existing treatment options. The investment enables NightBalance to further develop the product and introduce it on the market.
Zibber provides image telephony and monitoring solutions for the elderly, caregivers and healthcare providers. Image telephony helps increase the sense of security and limits isolation. This increases the well-being of those needing care and leads to less demand for care in the professional circuit. Zibber is simple to use, based on open standards and always fits within the budget of caregivers and healthcare providers. The investment enables Zibber to contribute to remote care in the Netherlands by upscaling the current pilot projects with caregivers and healthcare providers.
The Health Innovation Fund invests in FABPulous, a spin-off of the University of Maastricht. FABPulous developed a test that can establish the presence of tissue damage in the heart within three minutes using two drops of blood taken by a finger prick. This test can therefore be an important tool for diagnosing a heart attack within the first line and immediately setting up adequate therapy. FABPulous will use this financing round to further develop and market the test.